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Combinations of different delivery routes for priming and boosting represent vaccination
strategies that can modulate magnitude, quality, and localization of the immune response.
A murine model was used to study T cell clonal expansion following intranasal (IN) or
subcutaneous (SC) priming, and secondary immune responses after boosting by either
homologous or heterologous routes. T cell primary activation was studied by using the
adoptive transfer model of ovalbumin-specific transgenic CD4+ T cells. Both IN and SC
immunization efficiently elicited, in the respective draining lymph nodes, primary clonal
expansion of antigen-specific CD4+ T cells that disseminated toward distal lymph nodes
(mesenteric and iliac) and the spleen. After boosting, a significant serum IgG response was
induced in all groups independent of the combination of immunization routes used, while
significant levels of local IgA were detected only in mice boosted by the IN route. Mucosal
priming drove a strongerTh1 polarization than the systemic route, as shown by serum IgG
subclass analysis. IFN-gamma production was observed in splenocytes of all groups, while
prime-boost vaccine combinations that included the mucosal route, yielded higher levels
of IL-17. Memory lymphocytes were identified in both spleen and draining lymph nodes
in all immunized mice, with the highest number of IL-2 producing cells detected in mice
primed and boosted by the nasal route. This work shows the critical role of immunization
routes in modulating quality and localization of immune responses in prime-boost vaccine
strategies.
Keywords: prime-boost, T cell priming, mucosal immune response, nasal immunization, subcutaneous
immunization, cytokines
INTRODUCTION
Most licensed vaccines include a priming dose and at least one
boost of the same immunogen to generate an effective immune
response in terms of increasing magnitude, quality, and localiza-
tion. The prime-boost concept, traditionally based on the same
vaccine given multiple times over a certain period (homologous
prime-boost), is currently applied also to the administration of the
vaccine antigen in different formulations (heterologous prime-
boost) (Lu, 2009; Radosevic et al., 2009). Initially developed to
combine recombinant DNA priming with viral vector boosting
(McShane, 2002; Ranasinghe and Ramshaw, 2009), the heterolo-
gous prime-boost approach has now been applied to many dif-
ferent combinations of delivery systems and has been tested in
several clinical trials (Hill et al., 2010; Paris et al., 2010; Row-
land and McShane, 2011; O’Hara et al., 2012; Sheehy et al., 2012).
Results from the AIDS vaccine trial RV144 performed in Thai-
land show that a prime-boost regimen of two genetically engi-
neered vaccine candidates, that had failed on their own, lowered
the rate of HIV infection by about 31% (Rerks-Ngarm et al.,
2009). Prime-boost approaches are applied also in the field of
vaccination against tuberculosis, in which many human stud-
ies are investigating the utility of a “booster” subunit vaccine,
comprising both protein-adjuvant combinations or recombinant
viral vectors, to be used in BCG vaccinated people (Rowland
and McShane, 2011; Rowland et al., 2013; Tameris et al., 2013).
The heterologous prime-boost approach can also be achieved by
combining different routes of vaccination. This strategy, prin-
cipally based on the combination of mucosal and parenteral
delivery, has the advantage of inducing immune responses in
both the local and systemic compartments that are as strong or
stronger than those resulting from homologous mucosal or par-
enteral vaccination alone (McCluskie et al., 2002; Glynn et al.,
2005; Mapletoft et al., 2010; Pattani et al., 2012). Indeed, the use
of homologous or heterologous routes can impact on the effi-
ciency and the localization of the immune response to a vaccine
formulation.
Targeting mucosal sites by vaccination is important consid-
ering that over 90% of infections occur at or through mucosal
surfaces. Mucosal immunization has been demonstrated to effi-
ciently elicit humoral and cellular responses both locally and
systemically, as observed in animal models and in humans (Lycke,
2012). The nasal route of immunization has largely proved to
be effective in inducing memory immune responses both sys-
temically and locally, i.e., in the respiratory, genital, and intesti-
nal tracts (Zuercher, 2003; Neutra and Kozlowski, 2006; Ciabat-
tini et al., 2010). Limitations to the use of the nasal route are
generally related to the choice of adequate mucosal adjuvants
and delivery systems whose potency needs to be carefully bal-
anced with their potential toxicity (Couch, 2004; Lewis et al.,
2009).
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For the design of a prime-boost vaccination strategy, it is impor-
tant to characterize the early events that happen during the pri-
mary immune response, such as the CD4+ T cell clonal expansion
upon antigen-MHC class II complex recognition. T cell priming
influences both B and T cell activation and the subsequent differ-
entiation into effector and memory cells. Indeed, the frequency of
primed antigen-specific CD4+ T cells has been shown to correlate
with the intensity of the secondary responses and may be a predic-
tor of vaccine immunogenicity in humans (Galli et al., 2009). We
have previously investigated the antigen-specific CD4+ and CD8+
T cell primary activation upon mucosal immunization with solu-
ble antigen mixed with mucosal adjuvants or delivered by recombi-
nant bacteria, using the adoptive transfer model system (Medaglini
et al., 2006; Ciabattini et al., 2008b, 2010, 2011; Pettini et al., 2009).
Intranasal (IN) immunization, with both recombinant bacteria
or soluble antigen with CpG adjuvant, elicited an early antigen-
specific clonal expansion of T cells within lymphoid tissue draining
the immunization site and the subsequent dissemination of these
activated cells (CD45RB−CD44+CD62L+) toward distal lymph
nodes through the blood (Ciabattini et al., 2008b, 2010, 2011).
Homing of nasally primed T cells in distal iliac lymph nodes
was CD62L-dependent, while entry into mesenteric lymph nodes
depended on both CD62L and α4β7, as shown by in vivo antibody-
mediated inhibition of T cell trafficking (Ciabattini et al., 2011).
In the present work, the T cell clonal expansion following IN or
subcutaneous (SC) priming and the secondary immune response
after boosting by either the homologous or heterologous routes
was studied in mice. Ovalbumin (OVA) mixed with the synthetic
TLR9 agonist CpG oligodeoxynucleotide (ODN) 1826, widely
described as an effective adjuvant for both parenteral and mucosal
immunization (Tengvall et al., 2006; Bode et al., 2011), was used
as the model vaccine formulation. The antigen-specific CD4+ T
cell priming after IN or SC immunization was studied employ-
ing the adoptive transfer model of OVA-specific transgenic CD4+
T cells (Kearney et al., 1994; Pettini et al., 2009). The local and
systemic antibody responses, as well as the T cell response in the
spleen and in draining lymph nodes, were characterized following
homologous or heterologous combination of prime-boost routes.
MATERIALS AND METHODS
ANIMALS
Eight-weeks old female OT-II TCR-transgenic (H-2b), C57BL/6J,
and BALB/c mice, purchased from Charles River (Lecco, Italy),
were maintained under specific pathogen-free conditions in the
animal facilities at the University of Siena, and treated accord-
ing to national guidelines (Decreto Legislativo January 27, 1992
n. 116, implementing 86/609/CEE Directive). All animal studies
were approved by the Ethics Committee “Comitato Etico Locale
dell’Azienda Ospedaliera Universitaria Senese” and the Italian
Ministry of Health (number 4/2011, July 20, 2011).
ADOPTIVE TRANSFER OF TRANSGENIC CD4+ T CELLS AND PRIMING
STUDIES
Adoptive transfer experiments were performed as previously
described (Pettini et al., 2009). Briefly, lymphocytes collected
from OT-II transgenic mice were enriched for CD4+ T cells
and stained with carboxy-fluorescein diacetate succinimidyl ester
(CFSE, 7.5µM, Invitrogen). An amount of 2.5× 106 of CFSE-
labeled T cells was injected into the tail vein of each recipient
mouse. After 24 h, C57BL/6J mice were immunized with OVA
grade V (Sigma-Aldrich; 25µg/mouse) and CpG ODN1826 (TCC
ATG ACG TTC CTG ACG TT, hereafter CpG ODN; Eurofins
MWG Operon, Ebersberg, Germany; 20µg/mouse) by the IN
or SC routes. IN immunized mice were lightly anesthetized by
intraperitoneal injection of tiletamine and zolazepam hydrochlo-
ride (Zoletil 20, Laboratoires Virbac, France, 6 mg/kg) and xylazine
(Xilor 2%, Bio 98 Srl, Italy, 3 mg/kg), held in a vertical position and
then inoculated with drops into a single nostril with a total volume
of 20µl of Phosphate Buffered Saline (PBS) solution. SC immu-
nization was performed dorsally in the region of the neck in a total
volume of 100µl of PBS.
Groups of three mice were sacrificed 0, 3, 5, and 7 days follow-
ing immunization. Cervical (CLN), mediastinal (MedLN), axillary
(AxLN), iliac (ILN), mesenteric (MLN) lymph nodes, and spleen
(SPL) were harvested from each mouse and individually mashed
onto a nylon screen. Cells were washed twice in Hanks’ Balanced
Salt Solution (HBSS, Gibco), incubated with Fc-blocking solu-
tion [0.5 mg CD16/CD32 mAb (clone 93) (eBioscience, USA), 5%
v/v mouse serum, 5% v/v rat serum, 0.2% w/v sodium azide (all
from Sigma-Aldrich) in 100 ml of HBSS] for 30 min at 4 °C, and
stained with PerCP-conjugated anti-mouse CD4 (clone RM 4–5,
BD Pharmingen) for 30 min at 4 °C. Samples were analyzed by flow
cytometry (FACScalibur, Becton Dickinson, San Diego, CA, USA).
Data analysis was performed by using Flow Jo software (Tree Star,
Ashland, OR, USA).
IMMUNIZATION USING PRIME-BOOST COMBINATIONS AND SAMPLE
COLLECTION
BALB/c mice (six per group) were primed by the IN or SC route
with OVA grade V (100µg/mouse) mixed with the adjuvant CpG
ODN (20µg/mouse) at days 0 and 10 and boosted 7 weeks later by
the homologous (IN/IN, group 1 and SC/SC, group 3) or by the
heterologous route (IN/SC, group 2 and SC/IN, group 4), while
group 5 was left naive as control. Immunizations were performed
in a volume of 20 or 100µl of PBS for IN and SC immunizations,
respectively. Blood samples were taken from the temporal plexus
on days 0 and on weeks 3, 5, 7, 9, 11, 13, and sera were stored
at 4 °C. Nasal washes were performed at week 13, as previously
described (Ciabattini et al., 2008a).
ELISA
Serum OVA-specific IgG, IgG1, and IgG2a were determined by
ELISA, as previously described (Medaglini et al., 2001), coat-
ing plates with OVA (4µg/ml). OVA-specific IgG titers were
expressed as the reciprocal of the highest dilution with an optical
density value ≥0.2 after background subtraction. The concen-
tration of OVA-specific IgG1 and IgG2a was calculated using a
standard curve of mouse myeloma IgG1 and IgG2a (Southern
Biotechnology Associates, Birmingham, AL, USA).
Ovalbumin-specific IgA were assessed in nasal washes coating
plates with OVA (4µg/ml) and diluting samples 1:2 in duplicate.
Alkaline-phosphatase-conjugate goat anti-mouse IgA (Southern
Biotechnology Associates) were added diluted 1:1000, and the
optical density was recorded using Thermo Scientific Multiskan
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FC Microplate Photometer. The concentrations of OVA-specific
IgA were calculated against a standard curve of mouse myeloma
IgA (Southern Biotechnology Associates).
IL-2 ELISPOT
Lymphocytes were collected from cervical and mediastinal lymph
nodes and spleen at week 13. For IL-2 ELISPOT, 96-well nitrocel-
lulose plates (Milititer HA, Millipore, USA) were coated overnight
at 4 °C with 5µg/ml of purified rat IL-2 monoclonal antibody
(BD Pharmingen, USA). Free binding sites were blocked with
complete RPMI. Pooled lymphocytes were seeded in triplicate
starting from 3× 106 cells/well and diluted up to 3× 105 cells/well.
Cells were stimulated with 90µg/ml of OVA for 18 h at 37 °C in
5% CO2. After washing, plates were incubated with biotinylated
anti-mouse IL-2 monoclonal antibody and then with streptavidin-
horseradish peroxidase (all from BD Pharmingen, USA). The
enzyme reaction was developed by adding 1 mg/ml of the substrate
3,3′-diaminobenzidine (Sigma-Aldrich). Spots were counted with
an EliScan immunospot analyzer (A.EL.VIS,Hannover,Germany),
and data were expressed as spot forming units (SFU) per million
of cells.
CYTOKINE ASSAY
IFN-γ, IL-4, and IL-17A production were assessed in culture
supernatants of restimulated splenocytes by Bio-Plex cytokine
immunoassay. Pooled splenocytes from each group were cultured
with 90µg/ml of OVA in complete RPMI for 72 h at 37 °C in 5%
CO2, and supernatants were collected and stored at−80 °C. IFN-
γ, IL-4, and IL-17A cytokines were detected using the 3-plex assay
system (Bio-Rad), following the manufacturer’s protocol, and ana-
lyzed by Luminex 100 (Bio-Rad). Cytokine concentrations were
calculated based on standard curve data using Bio-Plex Manager
software (version 4.0).
STATISTICAL ANALYSIS
Percentages of antigen-specific proliferating T cells after IN or
SC priming were compared using the two-tailed Student’s t -
test. Sera were tested individually and values were expressed as
mean± standard error of the mean (SEM). Statistical differences
between antibodies among groups were assessed using one-way
analysis of variance (ANOVA) and Tukey’s post test for multiple
comparisons on log-transformed data. The two-tailed Student’s
t -test was used for analyzing differences in IgG titers at differ-
ent time points and for comparing values of OVA-specific IgG1
and IgG2a between nasally and subcutaneously primed mice. IL-2
production among different groups was analyzed using one-way
ANOVA and Tukey’s post test on log-transformed data. Statistical
significance was defined as P ≤ 0.05. Graphpad 4.0 software was
used for analysis.
RESULTS
ANTIGEN-SPECIFIC PRIMARY ACTIVATION OF CD4+ T CELLS
Both IN and SC routes of immunization yielded an efficient
primary activation of CD4+ T cells as demonstrated using the
adoptive transfer model of CFSE-labeled OVA-specific transgenic
CD4+ T cells. Three days after both IN and SC priming with OVA
and CpG ODN, antigen-specific clonally expanded T cells were
observed in CLN and MedLN (Figure 1A). The T cell proliferation
in draining CLN was more rapid following SC than IN immuniza-
tion, as shown by the higher number of cells within advanced cell
generations (Figure 1A) and the higher percentage of proliferating
T cells at day 3 (P≤ 0.001; Figure 1B). Priming by the SC, but not
the IN route, induced T cell expansion in AxLN, that act as drain-
ing lymph nodes upon immunization in the dorsal neck region
(Figures 1A,B). A significantly higher percentage of proliferating
cells after SC priming was also observed in distal lymph nodes and
FIGURE 1 | Clonal expansion of transgenic CD4+ T cells after IN or SC
priming. C57BL/6J mice, adoptively transferred with CFSE-labeled OT-II CD4+
T cells, were primed by the IN or SC routes with OVA mixed with the adjuvant
CpG ODN. OVA-specific proliferation was analyzed in T cells collected from
cervical (CLN), mediastinal (MedLN), axillary (AxLN), iliac (ILN), mesenteric
(MLN) lymph nodes, and spleen (SPL) at different time points. (A)
OVA-specific proliferation of OT-II CD4+ T cells detected by CFSE dilution in
lymphoid organs 3 days following IN (bottom histogram) or SC (middle
histogram) priming or in untreated mice (top histogram). (B) Time-course
analysis of the clonal expansion of OT-II CD4+ T cells following IN (filled circle)
or SC (empty square) priming with OVA and CpG ODN. The clonal expansion
was analyzed on days 0, 3, 5, and 7 post-immunization. Values reported on the
y axis indicate the percentage of proliferating OT-II cells compared to the total
transgenic cells detected in each lymph node or spleen. Values are expressed
as means±SEM of 2 independent experiments, each performed with three
animals. Two-tailed Student’s t -test was used for comparing values of
proliferating T cells between nasal and subcutaneous primed mice at each
time point. *P ≤0.05, **P ≤0.01, and ***P ≤0.001.
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in the SPL (P≤ 0.001 for ILN; P≤ 0.05 for MLN and SPL versus
IN immunized mice; Figure 1B). The presence of primed T cells at
distal sites is due to migration of proliferated T cells from draining
lymph nodes, as previously demonstrated (Ciabattini et al., 2011).
Nevertheless, studying the clonal expansion of OVA-specific T cells
at days 5 and 7 after immunization, we observed similar percent-
ages of dividing cells between the two groups (Figure 1B). The
percentage of dividing cells peaked at day 5 following both IN and
SC priming (with about 80% of divided T cells in CLN, MedLN,
ILN, and SPL), and persisted for at least 7 days (Figure 1B). As
expected, a significant difference was maintained only in AxLN
(P≤ 0.01; Figure 1B).
SECONDARY IMMUNE RESPONSES FOLLOWING HOMOLOGOUS OR
HETEROLOGOUS PRIME-BOOST COMBINATIONS
Systemic antibody response
Ovalbumin-specific serum antibody responses were assessed in
mice primed with OVA and CpG ODN by the IN or SC route
and boosted at week 7 by the homologous (IN/IN and SC/SC)
or heterologous (IN/SC and SC/IN) routes. A significant antigen-
specific IgG response, with a geometric mean titer (GMT) of about
1000, was observed in all groups after priming compared to naive
mice (P< 0.001; Figure 2A). Boosting resulted in a rapid increase
of the IgG titers which was comparable in all groups of immunized
animals. Serum antibody levels persisted in all groups 6 weeks after
boosting (Figure 2A). Even if the immune responses detected
in mice primed-boosted by the IN route were higher than the
other groups, no statistically significant difference was observed.
To study the type of Th response, the distribution of IgG subclasses
was assessed in the final sera (week 13) of all animals. Mice primed
by the SC route (SC/SC and SC/IN) produced higher levels of OVA-
specific IgG1 antibodies compared to mice primed by the nasal
route (IN/IN and IN/SC) which in turn developed a significantly
higher response of OVA-specific IgG2a (P ≤ 0.05; Table 1), as
shown by the ratio of IgG1/IgG2a subclasses (Figure 2B). This iso-
type switching suggests a stronger Th1 polarization in mucosally
primed mice.
Local antibody response
The study of antigen-specific IgA in nasal washes after IN or
SC boosting revealed that local antibody responses were essen-
tially dependent on mucosal boosting. A significantly higher IgA
response was observed in mice boosted by the nasal route, with
values of 5.32 ng/ml (IN/IN) and 4.32 ng/ml (SC/IN) of OVA-
specific IgA, compared to the naive group (P < 0.001 and P < 0.01,
respectively) and not in mice boosted by the SC route (SC/SC and
IN/SC; Figure 3). Moreover, the local IgA response elicited in mice
boosted by the nasal route was statistically higher than the one
induced in mice boosted by the systemic route (Figure 3).
Cellular immune response in spleen and lymph nodes
Antigen-specific memory cells were detected in the spleen and
draining lymph nodes (cervical and mediastinal) of mice immu-
nized by all different prime-boost combinations. After in vitro
restimulation with OVA antigen, all groups developed a signifi-
cantly higher number of IL-2 producing cells compared to naive
mice (Figures 4A,B). Mucosal priming and boosting generated
FIGURE 2 | OVA-specific serum antibody response. BALB/c mice
were immunized with OVA mixed with the adjuvant CpG ODN at days 0
and 10 by the IN or SC route followed by a boost at week 7 by the
homologous or heterologous route. Antibody response was assessed by
ELISA on individual serum samples. (A) OVA-specific IgG response
assessed in samples collected at weeks 0, 3, 5, 7, 9, 11, and 13.
Antibody titers were expressed as the reciprocal of the highest dilution
with an OD value ≥0.2 after background subtraction. Values are reported
as GMT±SEM. (B) Ratio of OVA-specific IgG1 and IgG2a subclasses
assessed in final serum of each animal. Data are reported as
mean±SEM for each group.
the highest number of responder lymphocytes in both spleen
(315 SFU/106 cells; P < 0.05 versus all the groups; Figure 4A)
and draining lymph nodes (61 SFU/106 cells; P < 0.05 versus mice
boosted by the SC route; Figure 4B). In the absence of antigenic
restimulation, no group developed a significant IL-2-response
(Figures 4A,B).
In order to characterize the quality of the cellular response,
the production of IFN-γ, IL-4, and IL-17A cytokines was assessed
in the culture supernatant of splenocytes pulsed with OVA. An
increase of IFN-γ levels was observed in all prime-boost combi-
nations compared to the control group (Figure 5A), while low
levels of IL-4 production were detected (Figure 5B). Interestingly,
higher levels of IL-17A were induced by immunization schemes
including the mucosal route compared to the homologous SC/SC
combination (Figure 5C).
DISCUSSION
In the present work we show that prime-boost combinations by
IN and SC routes affect the local and systemic immune responses
in mice.
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Table 1 | Serum total and OVA-specific IgG subclasses in immunized animalsa.
Animal groupb IgG1 (µg/ml) IgG2a (µg/ml)
OVA-specific Total OVA-specific Total
IN/IN 363±121 2780±493 147±26*c 850±86
IN/SC 266±132 2740±322 148±43* 909±216
SC/SC 435±68 3304±130 71±25 715±54
SC/IN 643±141 2805±121 65±29 596±24
Untreated <0.011 790±96 <0.03 192±27
aTotal and OVA-specific IgG1 and IgG2a antibodies assessed in the final sera (week 13) of each animal. Data reported as mean concentration (µg/ml)±SEM of each
group.
bAnimals were primed and boosted by homologous (IN/IN and SC/SC) or heterologous (IN/SC and SC/IN) routes; IN, intranasal immunization; SC, subcutaneous
immunization.
cTwo-tailed Student’s t-test was used for comparing values of OVA-specific IgG1 and IgG2a between nasally versus subcutaneously primed mice. *P≤0.05.
FIGURE 3 | OVA-specific local IgA. BALB/c mice were immunized with
OVA mixed with the adjuvant CpG ODN at days 0 and 10 by the IN or SC
route followed by a boost at week 7 by the homologous or heterologous
route. OVA-specific IgA were assessed in nasal washes collected at
sacrifice (week 13). Bars represents the mean value of OVA-specific IgA
concentration per each group. One-way ANOVA and Tukey’s post test for
multiple comparisons were used for comparing antibody response in
different groups. *P <0.05, **P <0.01, and ***P <0.001.
Essential parameters of long-term vaccine efficacy are the per-
sistence of antibodies and the generation of immune memory
cells. T cells are crucial to the induction of high-affinity antibod-
ies and immune memory, thus being important effector players
since the primary immunization. Here, we have explored the pri-
mary expansion of antigen-specific CD4+ T cells following IN
and SC immunization in mice adoptively transferred with OT-II
transgenic cells. A more rapid proliferation within draining lymph
nodes and dissemination toward distal sites was observed in sub-
cutaneously primed mice. However, 7 days after immunization the
percentage of antigen-specific divided cells, detected in draining
and distal lymphoid compartments, was not significantly differ-
ent between the two routes, except for AxLN, that act as draining
lymph nodes following SC but not IN immunization. Subcuta-
neously injected soluble antigens are rapidly carried from the
injection site into draining lymph nodes, through afferent lym-
phatic vessels, where they are taken up by resident dendritic cells
that produce antigen-MHC II complexes, with a peak reached 3 h
after immunization (Itano et al., 2003). Therefore, it is possible
that the antigen-presentation upon SC immunization is faster than
the IN delivery route. The proliferative response observed here
in C57BL/6J mice adoptively transferred with transgenic OT-II
cells is comparable to the one observed in BALB/c mice adop-
tively transferred with DO11.10 transgenic cells following nasal
immunization with either soluble OVA and CpG ODN (data not
shown) or OVA-expressing recombinant S. gordonii (Medaglini
et al., 2006).
The use of the adoptive transfer technique for studying in vivo
T cell primary activation allows to enrich the very low frequency of
naïve antigen-specific T cells, and therefore to characterize in vivo
their clonal expansion in different organs. Obviously, the transfer
of a high number of naive T cells into recipient mice may alter the
physiological conditions; to overcome this possible limitation and
assess the antigen-specific primary T cell activation in vivo fol-
lowing vaccination, we are currently further investigating mucosal
T cell priming with MHC class II tetramers specific for relevant
vaccine antigens.
Comparable levels of serum IgG antibodies were induced by
both IN and SC primary immunization, which persisted for
at least 7 weeks after priming. Booster vaccination induced a
significant and rapid increase of the serum IgG antibody lev-
els independently of prime-boost combinations. Interestingly,
mucosal prime-boost schedule (IN/IN) was as immunogenic as
the parental one (SC/SC). Regarding the IgG subclasses switch-
ing, it is known that Th1/Th2 polarization is influenced by factors
such as the genetic predisposition of mice, the vaccine formula-
tion (McCluskie et al., 2002) and the immunization route. BALB/c
mice are genetically polarized toward a Th2 response (Finnegan
et al., 1999), while the CpG adjuvant promotes the generation of
a Th1 response (Chu et al., 1997; Tengvall et al., 2006). In this
study, by maintaining the same vaccine formulation for priming
and booster immunizations, we analyzed the role of the immu-
nization route, observing that (i) IN and SC routes differently
affect the immunoglobulin class switching, and (ii) the isotype
switching is driven by the priming and not booster immunization.
Mice primed by the nasal route developed higher OVA-specific
IgG2a antibodies compared to parenterally primed mice that in
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FIGURE 4 | OVA-specific lymphocyte response determined by IL-2
ELISPOT assay. BALB/c mice were immunized with OVA mixed with the
adjuvant CpG ODN at days 0 and 10 by the IN or SC route followed by a
boost at week 7 by the homologous or heterologous route. Lymphocytes
were obtained from spleens (A) and pooled cervical and mediastinal
lymph nodes (B) at week 13, and the IL-2 production was evaluated
following OVA restimulation by ELISPOT assay. The number of
antigen-specific spot forming units (SFU) of OVA-restimulated (black
histograms) and unstimulated (white histograms) cells is shown. Bars
represent the mean number of SFU/106 cells±SEM of triplicate samples.
One-way ANOVA and Tukey’s post test for multiple comparisons was
performed for all groups. The numbers above the error bars indicate which
groups (1–5) are statistically different. Statistical significance was defined
as P <0.05.
turns produced higher IgG1. Nasal priming induced therefore a
stronger Th1 polarization, as already observed with other anti-
gens and vaccine formulations (Ricci et al., 2000; Medaglini et al.,
2001). The Th1 polarization was confirmed by the high produc-
tion of IFN-γ and very low release of IL-4 in culture supernatants
of splenocytes in all immunized groups. A third type of inducible
T cell immunity involves IL-17 production, a cytokine initially
found to play a central role in inflammation and autoimmunity
and now recognized as an important cytokine involved in nor-
mal responses to pathogens, such as those of the respiratory tract
(Lu et al., 2008; Sonnenberg and Weiner, 2009), and in protec-
tive immunity induced by vaccination (Bettelli et al., 2007; Moffitt
et al., 2011). Here we report the production of IL-17A in mice
immunized by the IN route, while a lower IL-17A response was
observed in mice primed-boosted by the SC route. These data,
showing that nasal immunization promotes IL-17 production, are
in line with previous studies performed with different adjuvants
FIGURE 5 | Cytokine production in culture supernatant of splenocytes.
IFN-γ (A), IL-4 (B), and IL-17A (C) were detected by Bio-Plex immunoassay
in culture supernatants of pooled splenocytes restimulated with OVA (as
described in Materials and Methods). Bars represent the mean
concentration±SD of duplicate samples.
including CpG (Zygmunt et al., 2009; Bielinska et al., 2010; Arias
et al., 2012).
The analysis of the prime-boost combinations showed also
that the booster route, more than the priming route, affects the
induction of local immune response, supporting previous data
obtained with different vaccine formulations (McCluskie et al.,
2002). Local antigen-specific IgA, indicative of effector plasma
cells in the nasal mucosa, were detected only when mice were
boosted by the nasal route. Mucosal priming enhanced the local
IgA response when nasally boosted, but was not sufficient with-
out the mucosal booster immunization as shown by the IN/SC
group. Interestingly, mice primed and boosted by the SC route did
not produce significant nasal IgA antibodies, even if an efficient
T cell priming had occurred in cervical and mediastinal lymph
nodes, as demonstrated by the T cell clonal expansion data. This
suggests that the nasal boost is essential for stimulating plasma
cells capable of homing to the nasal mucosa and releasing local
IgA. Lymphocytes collected from cervical and mediastinal lymph
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nodes were responsive to in vitro restimulation with OVA in all
groups, with the highest number of IL-2 producing cells detected
in mice boosted by the nasal route. These data are in line with
what was recently observed by the vaginal route, where vaginal
booster immunization was necessary to elicit an effector response
in the vaginal tract, both in terms of local antibodies and T
cells (Marks et al., 2011). Thus, our data confirm the importance
of the booster immunization route to elicit a mucosal effector
response.
In summary, in our system we observed that (i) both IN and
SC immunizations prime antigen-specific CD4+ T cells and that
these cells can be efficiently boosted by either homologous or het-
erologous routes; (ii) the route used for priming and not for
boosting influences the Th1 or Th2 skewing, with a stronger
Th1 polarization in mucosally primed mice; (iii) mice primed
and/or boosted by the nasal route produce higher levels of IL-17A
than mice primed-boosted systemically; and (iv) systemic immune
responses are efficiently elicited by all prime-boost combinations,
while local effector responses are mainly dependent on mucosal
boosting.
Taken together, these results highlight the critical role of the
priming and booster immunization routes in modulating the qual-
ity and the localization of the secondary immune responses, and
that prime-boost routes should be considered for the rational
design of a vaccination strategy.
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